by Marie Gethins
Positive indicators for stem cell product market entry and utilization dominated the Third Annual Stem Cell Summit, hosted by RRY...
Stem Cell Summit 2008: Moving from Process to Product
More than 40 companies revealed promising research and clinical results at the 2008 Stem Cell Summit in February. Perhaps most impressive was the number of stem cell therapies already in use or tantalizingly close to market launch.
More from Archive
More from Medtech Insight
• By
In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.
• By
The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.
• By
For the full year, the company now expects tariffs to increase the cost of sales by approximately 1% of revenue, plus or minus 20 basis points. This is lower than the previous estimate of approximately 1.7% of revenue. The updated gross margin guidance for 2025 is 66%-67%, up from 65%-66.5%.